Alphabet Soup - Biomarker testing for colon and rectal cancer patients - KRAS, RAS
Part 2 Colorectal Cancer Thursday, July 26, 2012 7:30 PM – 8:30 PM ET RTP TV: Emerging Treatment Strategies in Colorectal Cancer.
1 O n c o l o Together for y LOncologia insieme per L*Aquila G Bruera, D Di Giacomo & E Ricevuto Medical Oncology Department Experimental.
What's New in Colorectal Cancer Research?
An Application of Evidence-Based Marginal Analysis: Assessing the ...
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / NO16966, a randomized phase III trial in first-line metastatic.
S. K. Anderson 1, J. M. Lafky 1, X. W. Carrero 1, T. K. Kimlinger 1, T. M. Halling 1, S. Kumar 1, P. J. Flynn 2, H. M. Gross 3, K. A. Jaeckle 4, J. C.
Bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized.
Abstract (updated)
1 Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology.
Disclosures
